<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7851">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883337</url>
  </required_header>
  <id_info>
    <org_study_id>EFC10891</org_study_id>
    <secondary_id>2008-006226-34</secondary_id>
    <nct_id>NCT00883337</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis</brief_title>
  <acronym>TENERE</acronym>
  <official_title>A Multi-center, Randomized, Parallel-group, Rater-blinded Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Plus a Long Term Extension Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective was to assess the effectiveness evaluated by the time to failure of two
      doses of teriflunomide in comparison to interferon beta-1a in patients with relapsing
      Multiple Sclerosis [MS].

      Secondary objectives were:

        -  To assess the effect of the two doses in comparison to interferon beta-1a on:

             -  Frequency of relapses,

             -  Fatigue,

             -  Patient's satisfaction with treatment.

        -  To evaluate the safety and tolerability of the two doses in comparison to interferon
           beta-1a.

      The study consisted of a core treatment period with a common end date defined as 48 weeks
      after randomization of the last participant, followed by an optional long-term extension
      treatment period until teriflunomide is commercially available in accordance with local
      regulations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The core treatment period per participant was variable depending on the enrollment in the
      study (maximum of approximatively 118 weeks). The two doses of teriflunomide were
      administered in double-blind fashion, whereas interferon beta-1a (Rebif®) was open-label.

      The opportunity to continue with the highest dose of teriflunomide in open-label fashion was
      offered to the participants who successfully completed treatment in the core study.

      The overall treatment period was followed by a 4-week elimination follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overview of Failures</measure>
    <time_frame>Core treatment period between 48 and 118 weeks depending on when the participant was enrolled</time_frame>
    <safety_issue>No</safety_issue>
    <description>Failure was defined as the first occurence of confirmed relapse or permanent treatment discontinuation (for any cause) which ever came first. If no events occurred, the participant was considered free of failure.
Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever - was to be confirmed by an increase in Expanded Disability Status Scale [EDSS] score or Functional System scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Failure: Kaplan-Meier Estimates of the Rate of Failure at Timepoints</measure>
    <time_frame>Core treatment period between 48 and 118 weeks depending on when the participant was enrolled</time_frame>
    <safety_issue>No</safety_issue>
    <description>Probability of disability progression at 24, 48 and 96 weeks was estimated using Kaplan-Meier method on the time to failure defined as the time from randomization to failure. Participants free of failure were censored at the date of last treatment.
Kaplan-Meier method consists in computing probabilities of non occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t. Probability of event at time t is 1 minus the probability of being event-free for the amount of time t.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Relapse Rate [ARR]: Poisson Regression Estimates</measure>
    <time_frame>Core treatment period between 48 and 118 weeks depending on when the participant was enrolled</time_frame>
    <safety_issue>No</safety_issue>
    <description>ARR is obtained from the total number of confirmed relapses that occured during the treatment period divided by the sum of the treatment durations.
To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrollment and baseline EDSS stratum as covariates).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fatigue Impact Scale (FIS) Total Score</measure>
    <time_frame>baseline (before randomization) and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>FIS is a subject-reported scale that qualifies the impact of fatigue on daily life in patients with MS. It consists of 40 statements that measure fatigue in three areas; physical, cognitive, and social.
FIS total score ranges from 0 (no problem) to 160 (extreme problem).
Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on FIS total score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication [TSQM] Scores</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>TSQM version 1.4 is an instrument to assess patients' satisfaction with medication. It consists of 13 questions that cover three dimensions (effectiveness, side effects and convenience) plus a global satisfaction question.
Four scores ranging from 0 to 100 (extremely satisfied) are obtained.
Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on TSQM score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction as factors).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overview of Adverse Events [AE]</measure>
    <time_frame>from first study drug intake up to 112 days after last intake in the core treatment period or up to first intake in the extension treatment period, whichever occurred first</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Teriflunomide 7 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriflunomide 7 mg once daily (core treatment period),
then optional,
Teriflunomide 14 mg once daily (extension treatment period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriflunomide 14 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriflunomide 14 mg once daily (core treatment period),
then optional,
Teriflunomide 14 mg once daily (extension treatment period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN-β-1a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interferon β-1a 3 times a week (core treatment period),
then optional,
Teriflunomide 14 mg once daily (extension treatment period).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon β-1a</intervention_name>
    <description>Sterile preservative-free solution packaged in graduated pre-filled syringes
Subcutaneous injection
Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®</description>
    <arm_group_label>IFN-β-1a</arm_group_label>
    <other_name>Rebif®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teriflunomide</intervention_name>
    <description>Film-coated tablet
Oral administration</description>
    <arm_group_label>Teriflunomide 7 mg</arm_group_label>
    <arm_group_label>Teriflunomide 14 mg</arm_group_label>
    <arm_group_label>IFN-β-1a</arm_group_label>
    <other_name>HMR1726</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing form of MS meeting McDonald's criteria for MS diagnosis and Expanded
             Disability Status Scale [EDSS] score ≤5.5 at screening visit.

        Exclusion Criteria:

          -  Significantly impaired bone marrow function or, significant anemia, leukopenia or
             thrombocytopenia;

          -  Persistent significant or severe infection;

          -  Liver function impairment or known history of hepatitis;

          -  Use of adrenocorticotrophic hormone [ACTH] or systemic corticosteroids for 2 weeks
             prior to randomization;

          -  Human immunodeficiency virus [HIV] positive;

          -  Prior use of Rebif®, or prior or concomitant use of other interferons in the 3 months
             prior to randomization;

          -  Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant
             agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate,
             mycophenolate, or natalizumab;

          -  Pregnant or breast-feeding woman;

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 056003</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056001</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056002</name>
      <address>
        <city>Hasselt</city>
        <zip>B-3590</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124002</name>
      <address>
        <city>London</city>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124003</name>
      <address>
        <city>Lévis</city>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124004</name>
      <address>
        <city>St. John'S</city>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203004</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203003</name>
      <address>
        <city>Praha 10</city>
        <zip>10034</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203002</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250003</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250005</name>
      <address>
        <city>Clermont Ferrand Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250004</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250002</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276003</name>
      <address>
        <city>Bad Mergentheim</city>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276011</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276012</name>
      <address>
        <city>Berlin</city>
        <zip>12099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276005</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276007</name>
      <address>
        <city>Erbach</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276006</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276004</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276010</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276009</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276002</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300001</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300002</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348001</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348005</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348003</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348002</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348007</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 348004</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380010</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380005</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380008</name>
      <address>
        <city>Cagliari</city>
        <zip>09126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380003</name>
      <address>
        <city>Cefalù</city>
        <zip>90015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380007</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380001</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380004</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380002</name>
      <address>
        <city>Roma</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380006</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616002</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616004</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616003</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616001</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724007</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724001</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724002</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724003</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 756002</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 788002</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826002</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826003</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 5BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Tunisia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 1, 2015</lastchanged_date>
  <firstreceived_date>April 16, 2009</firstreceived_date>
  <firstreceived_results_date>October 3, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing-remitting multiple sclerosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon beta 1a</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment initiated in April 2009 was completed in July 2010. A total of 369 patients were screened at 54 sites in 13 countries.
The common end date for the core treatment period was on 14 September 2011 (maximum treatment duration of 115 weeks).
The optional long-term extension study is still ongoing.</recruitment_details>
      <pre_assignment_details>Randomization was stratified by country and baseline disability (Expanded Disability Status Scale [EDSS] score ≤3.5 or &gt;3.5).
Assignment to groups was done centrally using an Interactive Voice Response System (IVRS] in a 1:1:1 ratio after confirmation of the selection criteria.
324 participants were randomized at 53 sites.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Teriflunomide 7 mg</title>
          <description>Teriflunomide 7 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>Teriflunomide 14 mg</title>
          <description>Teriflunomide 14 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>IFN-β-1a</title>
          <description>Interferon β-1a 3 times a week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="111">One participant received teriflunomide 7 mg instead of teriflunomide 14 mg</participants>
                <participants group_id="P3" count="101">3 participants refused treatment with Rebif®</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89">Completed core treatment period</participants>
                <participants group_id="P2" count="89">Completed core treatment period</participants>
                <participants group_id="P3" count="71">Completed core treatment period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Wish to be pregnant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Teriflunomide 7 mg</title>
          <description>Teriflunomide 7 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Teriflunomide 14 mg</title>
          <description>Teriflunomide 14 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>IFN-β-1a</title>
          <description>Interferon β-1a 3 times a week</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="109"/>
                <measurement group_id="B2" value="111"/>
                <measurement group_id="B3" value="104"/>
                <measurement group_id="B4" value="324"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="32.5" spread="9.2"/>
                <measurement group_id="B2" value="36.8" spread="10.3"/>
                <measurement group_id="B3" value="37.0" spread="10.6"/>
                <measurement group_id="B4" value="36.3" spread="10.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="70"/>
                <measurement group_id="B2" value="78"/>
                <measurement group_id="B3" value="71"/>
                <measurement group_id="B4" value="219"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="33"/>
                <measurement group_id="B4" value="105"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of enrollment</title>
          <description>Due the small sample size in some countries, the countries were pooled as follows:
North America: Canada;
Eastern Europe: Czech Republic, Greece, Hungary and Poland;
Western Europe: Belgium, France, Germany, Italy, Spain, Switzerland and United Kingdon;
'*' the only participant in Tunisia was included in the Western Europe group.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>North America</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="7"/>
                <measurement group_id="B4" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Eastern Europe</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
                <measurement group_id="B2" value="41"/>
                <measurement group_id="B3" value="35"/>
                <measurement group_id="B4" value="115"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Western Europe*</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="62"/>
                <measurement group_id="B2" value="64"/>
                <measurement group_id="B3" value="62"/>
                <measurement group_id="B4" value="188"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Time since first diagnosis of Multiple Sclerosis [MS]</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3.72" spread="5.19"/>
                <measurement group_id="B2" value="3.68" spread="6.24"/>
                <measurement group_id="B3" value="3.82" spread="5.69"/>
                <measurement group_id="B4" value="3.74" spread="5.71"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Number of MS relapses</title>
          <units>relapses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <sub_title>Within the past year</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1" lower_limit="0" upper_limit="3"/>
                <measurement group_id="B2" value="1" lower_limit="0" upper_limit="4"/>
                <measurement group_id="B3" value="1" lower_limit="0" upper_limit="5"/>
                <measurement group_id="B4" value="1" lower_limit="0" upper_limit="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Within the past 2 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2" lower_limit="0" upper_limit="4"/>
                <measurement group_id="B2" value="2" lower_limit="0" upper_limit="4"/>
                <measurement group_id="B3" value="2" lower_limit="0" upper_limit="6"/>
                <measurement group_id="B4" value="2" lower_limit="0" upper_limit="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Time since most recent MS relapse onset</title>
          <description>The information was not available for one participant in the Teriflunomide 14 mg group</description>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9.00" spread="13.96"/>
                <measurement group_id="B2" value="7.90" spread="10.34"/>
                <measurement group_id="B3" value="9.79" spread="10.72"/>
                <measurement group_id="B4" value="8.88" spread="11.79"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>MS subtype</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Relapsing Remitting</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="109"/>
                <measurement group_id="B2" value="108"/>
                <measurement group_id="B3" value="104"/>
                <measurement group_id="B4" value="321"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Secondary Progressive</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Progressive Relapsing</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Baseline EDSS score</title>
          <description>EDSS is an ordinal scale in half-point increments that qualifies disability in patients with MS. It consists of 8 ordinal rating scales assessing seven functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation.
EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS).</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>≤3.5</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="96"/>
                <measurement group_id="B2" value="95"/>
                <measurement group_id="B3" value="93"/>
                <measurement group_id="B4" value="284"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;3.5</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="11"/>
                <measurement group_id="B4" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overview of Failures</title>
        <description>Failure was defined as the first occurence of confirmed relapse or permanent treatment discontinuation (for any cause) which ever came first. If no events occurred, the participant was considered free of failure.
Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever - was to be confirmed by an increase in Expanded Disability Status Scale [EDSS] score or Functional System scores.</description>
        <time_frame>Core treatment period between 48 and 118 weeks depending on when the participant was enrolled</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population: all randomized participants. Participants were considered in the treatment group to which they were randomized regardless of the drug they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriflunomide 7 mg</title>
            <description>Teriflunomide 7 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 14 mg</title>
            <description>Teriflunomide 14 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>IFN-β-1a</title>
            <description>Interferon β-1a 3 times a week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                  <measurement group_id="O2" value="111"/>
                  <measurement group_id="O3" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overview of Failures</title>
            <description>Failure was defined as the first occurence of confirmed relapse or permanent treatment discontinuation (for any cause) which ever came first. If no events occurred, the participant was considered free of failure.
Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever - was to be confirmed by an increase in Expanded Disability Status Scale [EDSS] score or Functional System scores.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="42"/>
                  <measurement group_id="O3" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Free of failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="69"/>
                  <measurement group_id="O3" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Failure: Kaplan-Meier Estimates of the Rate of Failure at Timepoints</title>
        <description>Probability of disability progression at 24, 48 and 96 weeks was estimated using Kaplan-Meier method on the time to failure defined as the time from randomization to failure. Participants free of failure were censored at the date of last treatment.
Kaplan-Meier method consists in computing probabilities of non occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t. Probability of event at time t is 1 minus the probability of being event-free for the amount of time t.</description>
        <time_frame>Core treatment period between 48 and 118 weeks depending on when the participant was enrolled</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Teriflunomide 7 mg</title>
            <description>Teriflunomide 7 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 14 mg</title>
            <description>Teriflunomide 14 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>IFN-β-1a</title>
            <description>Interferon β-1a 3 times a week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                  <measurement group_id="O2" value="111"/>
                  <measurement group_id="O3" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Failure: Kaplan-Meier Estimates of the Rate of Failure at Timepoints</title>
            <description>Probability of disability progression at 24, 48 and 96 weeks was estimated using Kaplan-Meier method on the time to failure defined as the time from randomization to failure. Participants free of failure were censored at the date of last treatment.
Kaplan-Meier method consists in computing probabilities of non occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t. Probability of event at time t is 1 minus the probability of being event-free for the amount of time t.</description>
            <units>percent probability</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Probability of failure at 24 weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.7" lower_limit="17.5" upper_limit="33.9"/>
                  <measurement group_id="O2" value="24.3" lower_limit="16.3" upper_limit="32.3"/>
                  <measurement group_id="O3" value="29.8" lower_limit="21.0" upper_limit="38.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Probability of failure at 48 weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35.8" lower_limit="26.8" upper_limit="44.8"/>
                  <measurement group_id="O2" value="33.3" lower_limit="24.6" upper_limit="42.1"/>
                  <measurement group_id="O3" value="36.5" lower_limit="27.3" upper_limit="45.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Probability of failure at 96 weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58.8" lower_limit="46.1" upper_limit="71.4"/>
                  <measurement group_id="O2" value="41.1" lower_limit="30.9" upper_limit="51.4"/>
                  <measurement group_id="O3" value="44.4" lower_limit="34.3" upper_limit="54.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study was sized to detect a difference between Teriflunomide and Rebif groups in the time to failure at a significance level of 0.025 with a power of 81%.
Null hypothesis:
H1: No difference between Teriflunomide 14 mg and Rebif
H2: No difference between Teriflunomide 7 mg and Rebif</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5953</p_value>
            <p_value_desc>Hochberg testing procedure:
a-priori threshold for statistical significance ≤0.05 for the largest p-value of the 2 pair-wise comparisons
a-priori threshold for statistical significance ≤0.025 for the other p-value if the largest p-value &gt;0.05</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Two-sided Log Rank test with the region of enrollment and baseline EDSS stratum as stratification factors</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis:
H1: No difference between Teriflunomide 14 mg and Rebif
H2: No difference between Teriflunomide 7 mg and Rebif</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5190</p_value>
            <p_value_desc>Hochberg testing procedure:
a-priori threshold for statistical significance ≤0.05 for the largest p-value of the 2 pair-wise comparisons
a-priori threshold for statistical significance ≤0.025 for the other p-value if the largest p-value &gt;0.05</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Two-sided Log Rank test with the region of enrollment and baseline EDSS stratum as stratification factors</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Relapse Rate [ARR]: Poisson Regression Estimates</title>
        <description>ARR is obtained from the total number of confirmed relapses that occured during the treatment period divided by the sum of the treatment durations.
To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrollment and baseline EDSS stratum as covariates).</description>
        <time_frame>Core treatment period between 48 and 118 weeks depending on when the participant was enrolled</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Teriflunomide 7 mg</title>
            <description>Teriflunomide 7 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 14 mg</title>
            <description>Teriflunomide 14 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>IFN-β-1a</title>
            <description>Interferon β-1a 3 times a week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                  <measurement group_id="O2" value="111"/>
                  <measurement group_id="O3" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Annualized Relapse Rate [ARR]: Poisson Regression Estimates</title>
            <description>ARR is obtained from the total number of confirmed relapses that occured during the treatment period divided by the sum of the treatment durations.
To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrollment and baseline EDSS stratum as covariates).</description>
            <units>relapses per year</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.410" lower_limit="0.265" upper_limit="0.636"/>
                  <measurement group_id="O2" value="0.259" lower_limit="0.153" upper_limit="0.438"/>
                  <measurement group_id="O3" value="0.216" lower_limit="0.113" upper_limit="0.415"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fatigue Impact Scale (FIS) Total Score</title>
        <description>FIS is a subject-reported scale that qualifies the impact of fatigue on daily life in patients with MS. It consists of 40 statements that measure fatigue in three areas; physical, cognitive, and social.
FIS total score ranges from 0 (no problem) to 160 (extreme problem).
Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on FIS total score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors).</description>
        <time_frame>baseline (before randomization) and 48 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Teriflunomide 7 mg</title>
            <description>Teriflunomide 7 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 14 mg</title>
            <description>Teriflunomide 14 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>IFN-β-1a</title>
            <description>Interferon β-1a 3 times a week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                  <measurement group_id="O2" value="111"/>
                  <measurement group_id="O3" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Fatigue Impact Scale (FIS) Total Score</title>
            <description>FIS is a subject-reported scale that qualifies the impact of fatigue on daily life in patients with MS. It consists of 40 statements that measure fatigue in three areas; physical, cognitive, and social.
FIS total score ranges from 0 (no problem) to 160 (extreme problem).
Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on FIS total score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors).</description>
            <units>units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.97" spread="2.96" lower_limit="-56" upper_limit="62"/>
                  <measurement group_id="O2" value="4.10" spread="3.03" lower_limit="-75" upper_limit="67"/>
                  <measurement group_id="O3" value="9.10" spread="3.21" lower_limit="-53" upper_limit="98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction Questionnaire for Medication [TSQM] Scores</title>
        <description>TSQM version 1.4 is an instrument to assess patients' satisfaction with medication. It consists of 13 questions that cover three dimensions (effectiveness, side effects and convenience) plus a global satisfaction question.
Four scores ranging from 0 to 100 (extremely satisfied) are obtained.
Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on TSQM score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction as factors).</description>
        <time_frame>48 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Teriflunomide 7 mg</title>
            <description>Teriflunomide 7 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 14 mg</title>
            <description>Teriflunomide 14 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>IFN-β-1a</title>
            <description>Interferon β-1a 3 times a week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                  <measurement group_id="O2" value="111"/>
                  <measurement group_id="O3" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Treatment Satisfaction Questionnaire for Medication [TSQM] Scores</title>
            <description>TSQM version 1.4 is an instrument to assess patients' satisfaction with medication. It consists of 13 questions that cover three dimensions (effectiveness, side effects and convenience) plus a global satisfaction question.
Four scores ranging from 0 to 100 (extremely satisfied) are obtained.
Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on TSQM score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction as factors).</description>
            <units>units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Effectivness score</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67.25" spread="2.70" lower_limit="0" upper_limit="100"/>
                  <measurement group_id="O2" value="63.13" spread="2.75" lower_limit="0" upper_limit="100"/>
                  <measurement group_id="O3" value="59.30" spread="2.97" lower_limit="0" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Side effects score</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95.29" spread="2.31" lower_limit="43.8" upper_limit="100"/>
                  <measurement group_id="O2" value="93.15" spread="2.34" lower_limit="37.5" upper_limit="100"/>
                  <measurement group_id="O3" value="71.38" spread="2.50" lower_limit="18.8" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Convenience score</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88.30" spread="1.97" lower_limit="33.3" upper_limit="100"/>
                  <measurement group_id="O2" value="89.85" spread="1.98" lower_limit="55.6" upper_limit="100"/>
                  <measurement group_id="O3" value="61.90" spread="2.11" lower_limit="11.1" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Global satisfaction score</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68.29" spread="2.77" lower_limit="21.4" upper_limit="100"/>
                  <measurement group_id="O2" value="68.82" spread="2.78" lower_limit="35.7" upper_limit="100"/>
                  <measurement group_id="O3" value="60.98" spread="2.94" lower_limit="14.3" upper_limit="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overview of Adverse Events [AE]</title>
        <description>AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.</description>
        <time_frame>from first study drug intake up to 112 days after last intake in the core treatment period or up to first intake in the extension treatment period, whichever occurred first</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population: all randomized and treated participants. Participants were considered according to the drug actually received.
The participant randomized to Teriflunomide 14 mg group who received Teriflunomide 7 mg was analyzed in the Teriflunomide 7 mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriflunomide 7 mg</title>
            <description>Teriflunomide 7 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 14 mg</title>
            <description>Teriflunomide 14 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>IFN-β-1a</title>
            <description>Interferon β-1a 3 times a week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="110"/>
                  <measurement group_id="O2" value="110"/>
                  <measurement group_id="O3" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overview of Adverse Events [AE]</title>
            <description>AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="102"/>
                  <measurement group_id="O3" value="97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>- Any serious AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>- Any AE leading to death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>- Any AE leading to treatment discontinuation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE are collected from signature of the Informed Consent Form up to the last visit in the study.</time_frame>
      <desc>The analysis was performed on the safety population as previously defined and included all AE that developed or worsened from first study drug intake up to 112 days after last intake in the core treatment period or up to first intake in the extension study treatment period, whichever came first.</desc>
      <group_list>
        <group group_id="E1">
          <title>Teriflunomide 7 mg</title>
          <description>Teriflunomide 7 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Teriflunomide 14 mg</title>
          <description>Teriflunomide 14 mg once daily</description>
        </group>
        <group group_id="E3">
          <title>IFN-β-1a</title>
          <description>Interferon β-1a 3 times a week</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months after trial completion, the Investigator can present or publish results. The investigator provides the sponsor with a copy of the presentation or publication for review and comment at least 30 days in advance of its submission.
The sponsor can delay the submission for a period not exceeding 90 days to allow for filing a patent application or such other measures as sponsor deems appropriate to establish and preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>Contact_US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
